Soliton Inc, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center, announces that it has entered into a Manufacturing Services Agreement with Sanmina Corporation, a leading integrated manufacturing solutions provider, as it transitions to manufacturing for the limited launch of its Rapid Acoustic Pulse (RAP) device for tattoo removal expected in mid-2020.
Under the terms of the agreement, Sanmina Corporation will manufacture Soliton’s RAP device and replaceable cartridges.
“We are delighted to continue to partner with Sanmina Corporation as we begin our transition into the manufacturing phase of commercialization ahead of the planned mid-2020 limited launch of our unique RAP device,” Dr Chris Capelli, Soliton’s President, CEO and co-founder, says in a media release.
“Sanmina’s expertise and world-class service are a great match for Soliton’s innovative device, which is FDA-cleared for tattoo removal and we believe has potential in additional aesthetic indications including cellulite removal and fibrotic scarring, and we look forward to working with them in the years ahead.”
[Source(s): Soliton Inc, PR Newswire]